SUBSCRIBE Blog with us: BLOGbiotech

GEN News Highlights

• Email
• Print
• Share
• More GEN News Highlights

Oct 14 2009, 11:00 AM EST

Galapagos and Merck & Co. Expand Existing Metabolic Disease Alliance to Cover Atherosclerosis

GEN News Highlights

Galapagos and Merck & Co. expanded their existing global collaboration in metabolic diseases to cover the development of new small molecule candidates against atherosclerosis. The original deal, signed in January, covered obesity and diabetes.

The wider collaboration could see Galapagos’ research, regulatory, and sales milestone payments double to over E400 million, or roughly $596.03 million.

Under terms of the expanded agreement, Galapagos will use its target discovery platform to identify and validate novel targets in all three indications. The company will also be responsible for the discovery of new drug candidates against these targets.

Merck will have an exclusive option to license each candidate for clinical development and commercialization worldwide. Galapagos is eligible to receive royalties upon commercialization of any products covered under the agreement.

 

♦♦♦
Related News
Merck Pays Depomed $10M for Patents to Expand Use of Antidiabetic (July 22, 2009)
Merck & Co. Funds Inflammatory Disease Drug Discovery at Galapagos (Apr. 20 2009)
Merck & Co. Pays Galapagos Roughly $2M to Kick Off Diabetes and Obesity Alliance (Jan. 9 2009)
Merck & Co. and Partners Identify a Gene-Expression Network that May Cause Obesity (Mar. 17, 2008)
Galapagos Licenses its Obesity and Diabetes Discovery Technology for Upwards of Euro 27.77M (Feb. 1 2007)

 

• Email
• Print
• Share
• More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:
	HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR